BTIG analyst Ryan Zimmerman initiated Organogenesis with a Buy rating and a price target of $12, citing the company's "expansive portfolio, history of execution, and improved capital structure". The analyst also notes that the company has been in the wound market since 1998, becoming "one of the largest pure-play companies in the fast growing and underpenetrated Advanced Wound Care market." Zimmerman further points to Organogenesis having built a $200M revenue business with its "stalwart wound products Apligraf and Dermagraft", with faster growing PuraPly for early wound intervention, and believes that it can capture more market share from some of its struggling competitors.